EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSAPOG00000019779
Gene Symbol: SIGMAR1
3 Cross references
205 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSAPOG00000009342
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSAPOG00000010561
Gene Symbol: LOC110960378
3 Cross references
245 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSAPOG00000022870
Gene Symbol: SCN4A
4 Cross references
187 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSAPOG00000021049
Gene Symbol: SCN8A
4 Cross references
219 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSAPOG00000006022
Gene Symbol: SCN8A
3 Cross references
218 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSAPOG00000006498
Gene Symbol: LOC110959976
3 Cross references
208 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSAPOG00000010425
Gene Symbol: LOC110957387
3 Cross references
204 Possible Orthologues:

Sodium-Dependent Serotonin Transporter-Like

Ensembl ID : ENSAPOG00000024477
Gene Symbol: LOC110948948
3 Cross references
203 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSAPOG00000015540
Gene Symbol: LOC110966837
3 Cross references
250 Possible Orthologues:

Sodium/glucose Cotransporter 2-Like

Ensembl ID : ENSAPOG00000000180
Gene Symbol: LOC110952879
3 Cross references
199 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSAPOG00000003901
Gene Symbol: LOC110961160
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).